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Impaired chondrocyte U3 snoRNA 
expression in osteoarthritis 
impacts the chondrocyte protein 
translation apparatus
Ellen G. J. Ripmeester1, Marjolein M. J. Caron1, G. G. H. van den Akker1, Don A. M. Surtel1, 
Andy Cremers1, Panagiotis Balaskas3, Philip Dyer3, Bas A. C. Housmans1, 
Alzbeta Chabronova1, Aibek Smagul3, Yongxiang fang3, Lodewijk W. van Rhijn1,2, 
Mandy J. Peffers3,4 & Tim J. M. Welting1,2,4*
Although pathways controlling ribosome activity have been described to regulate chondrocyte 
homeostasis in osteoarthritis, ribosome biogenesis in osteoarthritis is unexplored. We hypothesized 
that U3 snoRNA, a non-coding RNA involved in ribosomal RNA maturation, is critical for chondrocyte 
protein translation capacity in osteoarthritis. U3 snoRNA was one of a number of snoRNAs with 
decreased expression in osteoarthritic cartilage and osteoarthritic chondrocytes. OA synovial fluid 
impacted U3 snoRNA expression by affecting U3 snoRNA gene promoter activity, while BMP7 was 
able to increase its expression. Altering U3 snoRNA expression resulted in changes in chondrocyte 
phenotype. Interference with U3 snoRNA expression led to reduction of rRNA levels and translational 
capacity, whilst induced expression of U3 snoRNA was accompanied by increased 18S and 28S rRNA 
levels and elevated protein translation. Whole proteome analysis revealed a global impact of reduced 
U3 snoRNA expression on protein translational processes and inflammatory pathways. For the first 
time we demonstrate implications of a snoRNA in osteoarthritis chondrocyte biology and investigated 
its role in the chondrocyte differentiation status, rRNA levels and protein translational capacity.
Osteoarthritis (OA) is a chronic debilitating joint disease that is strongly associated with  ageing1,2. OA involves 
pathological cellular processes in all joint structures and affects articular cartilage integrity, leading to dys-
functional joint  articulation2. During OA development and progression, the articular chondrocyte’s phenotype 
 changes3–5 and presents with disturbed cellular homeostasis characterized by abnormal expression of (pre-)
hypertrophic-[RUNX2 (runt-related transcription factor 2); COL10A1 (type X collagen)], catabolic-[ALPL (alka-
line phosphatase); MMP13 (matrix metallopeptidase 13) and ADAMTS5 (a disintegrin and metalloproteinase 
with thrombospondin motifs 5) and inflammatory (COX2 (cyclooxygenase 2) and IL-6 (interleukin 6)] genes, 
while chondrogenic gene expression [SOX9 (SRY-box transcription factor 9); COL2A1 (type 2 collagen); ACAN 
(aggrecan) and NKX3-2 (NK3 homeobox 2)] is  attenuated3,4. The biomolecular processes that catalyze distur-
bances in the articular chondrocyte phenotype leading to OA are poorly understood, and it is expected that a 
comprehensive understanding of the avenues leading to disruption of articular chondrocyte homeostasis will 
provide important clues for future treatments.
Chondrocytes are specialized secretory cells, enabling the synthesis and maintenance of the protein-rich 
cartilage extracellular matrix (ECM). Disturbances in chondrocyte protein translation in cartilage development 
and OA are connected to mTOR (mammalian target of rapamycin)  activity6, endoplasmic reticulum  stress7, 
unfolded protein response and  apoptosis8. These responses change the downstream translational activity of the 
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biosynthesized ribosome. The assembled mammalian ribosome is built from ribosomal RNAs (rRNAs), together 
with at least 80 different protein  subunits9. In the ribosome the 18S rRNA guides the decoding of the mRNA 
message, while the 28S rRNA forms the core of the peptidyltransferase center that polymerizes the amino acid 
sequence encoded by the mRNA into functional proteins. Post-transcriptional maturation of rRNAs is an inte-
gral part of the biosynthesis of  ribosomes10–13 and ribonucleolytic processing of the major 47S rRNA precursor 
into mature 18S, 5.8S, and 28S rRNAs is rate-limiting for ribosome  biogenesis10. The U3 small nucleolar RNA 
(snoRNA) is a highly abundant and evolutionarily conserved box C/D-class snoRNA, guiding the endoribonu-
cleolytic processing of the 5′ external transcribed spacer (ETS) of the 47S pre-rRNA by base complementarity-
guided pre-rRNA substrate  recognition14 and plays a key role in the maturation of 18S  rRNA12,15. Although 
extensively studied in  yeast16, it was only recently demonstrated that U3 snoRNA is indispensable for rRNA 
maturation in human  cells16.
Pathways controlling ribosome activity have been described in the regulation of chondrocyte  homeostasis17,18. 
Here, we postulated that not only ribosome activity is involved in chondrocyte homeostasis, but that OA patho-
physiological situations can cause alterations in chondrocyte ribosome biogenesis with consequences for cellular 
protein translation. In this study we discovered that the chondrocyte expression of ribosome biogenesis factor U3 
snoRNA is impacted in OA cartilage and we investigated its connection with OA pathophysiological conditions 
in chondrocytes and its role in influencing rRNA levels and chondrocyte translation capacity.
Materials and methods
Cell culture. Human articular chondrocytes (HACs) were isolated from femoral cartilage from total knee 
arthroplasty for end‐stage OA (OA-HACs; average age 68.5 years with SD 8.2 years). Non-OA chondrocytes 
were isolated from cartilage of non-OA individuals undergoing anterior cruciate ligament repair (average age 
25.7 years with SD 17.9 years). Medical ethical approval for collecting and using HACs was received from the 
Medical Ethics Committee from the Maastricht University Medical Center (approval number 2017-0183). Dutch 
medical ethical guidelines were followed for studying human samples and informed consent was acquired. 
Chondrocyte isolation and culture was performed as described  previously5. SW1353 cells were purchased from 
ATCC (ATCC; Middlesex, UK) and cultured in a humidified atmosphere at 37 °C, 5%  CO2. Culture medium 
was Dulbecco’s Modified Eagle Medium (DMEM)/F-12 (Life Technologies, Waltham, Massachusetts, USA) sup-
plemented with 10% fetal calf serum (FCS; Sigma-Aldrich, Dorset, UK), 1% non-essential amino acids (NEAA; 
Life Technologies) and 1% penicillin/streptomycin (P/S, Invitrogen Life Technologies). In experiments non-OA 
chondrocytes were exposed to control (20% (v/v) of 0.9% NaCl), non-OA synovial fluid (non-OA SF; 20% (v/v); 
pool of ten donors; average age 56.7 years with SD 7.5 years; purchased from Articular Engineering, Northbrook, 
Illinois, USA) or OA synovial fluid (OA-SF; 20% (v/v); pool of six or ten donors; for ten-donors-pool average age 
65.4 years with SD 9.1 years; for six-donor-pool average age 73.0 years with SD 6.8 years; MEC approval 2017-
0183). The average age difference between the ten-donor-pools was not statistically significant (Mann Whitney, 
p = 0.069). SW1353 and non-OA HACs were exposed to BMP7 (R&D Systems, Minneapolis, Minnesota, USA).
Microarray. Cartilage biopsies were obtained from the femoral intercondylar notch of non-OA male 
human knees of young individuals undergoing anterior cruciate ligament repair surgery (n = 6; mean age ± SD 
22.7 ± 4.1 years). OA cartilage was obtained from male OA patients undergoing total knee arthroplasty (n = 6; 
mean age 66.4 ± 15.9 years). Sample characteristics; sample collection; RNA isolation of OA and healthy carti-
lage; the micro-array and data analysis have been performed as previously  reported19. The heat map of hierarchi-
cal clusters of correlations and PCA plot are shown in Supplementary Fig. 1. Medical ethical approval for collect-
ing and using cartilage biopsies was received from the Medical Ethics Committee from the Maastricht University 
Medical Center (approval number 08-04-028 and 14-4-038). Dutch medical ethical guidelines were followed for 
studying human samples and informed consent was acquired. Sequence data have been submitted to National 
Centre for Biotechnology Information Gene Expression Omnibus (NCBI GEO); E-MTAB-5715.
DMM. Mice (C57BL/6) were group housed in individually ventilated cages at a 12 h light/dark cycle, with 
ad libitum access to food and water. Under anesthesia, a 3 mm skin incision was made over the medial aspect of 
the patellar ligament through the joint capsule into the femorotibial joint of the left knee. The medial meniscoti-
bial ligament was transected to destabilize the cranial pole of the medial meniscus from the anterior tibial pla-
teau. In sham-operated mice (n = 3) the medial meniscotibial ligament was visualized but not transected. Mice 
were sacrificed 8 weeks post-surgery and stifles were fixated in phosphate-buffered 3.7% formalin. Ethical review 
was conducted by the University of Liverpool Animal Welfare and Ethical Review Body and ethical approval 
was obtained from the University of Liverpool (project license P74DC0667). All experimental protocols were 
performed in compliance with the UK Animals (Scientific Procedures) Act 1986 regulations.
U3 snoRNA in situ hybridization. Dissected stifles were decalcified in a 1:1 10% formalin (VWR, Rad-
nor, Pennsylvania, USA): 200 mM EDTA (VWR) for 3 weeks, embedded in paraffin and sectioned at 5 µm, 
three adjacent sections per slide. Following dewaxing sections were circled with a hydrophobic pen (Agilent, 
Santa Clara, California, US). U3 snoRNA in  situ hybridization was performed following the manufacturer’s 
instructions of the miRCURY LNA miRNA ISH Optimization kit (Qiagen, Hilden, Germany). Probe sequences 
(Eurogentec, Liège, Belgium) are shown in Supplementary Table 1. Detection was performed by ~ 1 h incubation 
at 37 °C with NBT/BCIP (Roche, Basel, Switzerland). Slides were washed with PBS-Tween (PBS-T; phosphate 
buffered saline with 0.1% Tween-20), counterstained 5 min 0.05% FastGreen, 5 min 0.05% Safranin O, dehy-
drated to xylene as standard and mounted with Pertex Mounting Medium.
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Knockdown and ectopic expression of U3 snoRNA. Transfection of non-OA HACs or SW1353 cells 
(seeded at 30,000 or 20,000 cells/cm2, respectively) with 100 nM of U3 snoRNA antisense oligonucleotide (ASO) 
or a scrambled version thereof (SCR) was performed using HiPerfect (Qiagen) according to the manufacturers’ 
protocol. Non-OA HACs were transfected after 8 h of prior serum starvation, while SW1353 cells were trans-
fected without prior serum starvation. Sequences of U3 snoRNA ASO and SCR (Eurogentec, Liège, Belgium) are 
shown in Supplementary Table 2. Transfection of non-OA HACs with a U3 snoRNA mini-gene was performed 
using Fugene6, following the manufacturers’ protocol (Promega, Madison, Wisconsin, USA). The U3 snoRNA 
mini-gene was synthesized (Genecust, Boynes, France) and cloned into the pUC57 vector. The mini-gene con-
sisted of the endogenous 500 nucleotide sequence upstream of the U3 snoRNA transcription start site, the pre-
U3 snoRNA sequence and followed by 250 nucleotides downstream of the transcription termination sequence. 
The U3 mini-gene construct was transfected at 10 ng plasmid/cm2 and because of the low amount of U3 snoRNA 
mini-gene supplemented with pGluc-basic-2-CMV (NEB, Ipswich, Massachusetts, USA) as carrier plasmid. In 
control conditions, only carrier pGluc-basic-2-CMV was transfected at equal total plasmid content as compared 
to the U3 mini-gene transfection.
U3 snoRNA promoter-reporter assay. The human U3 snoRNA gene promoter sequence was synthe-
sized (Genecust, Boynes, France) from the 500 nucleotide sequence upstream of the U3 snoRNA transcription 
start site of SNORD3A gene (Ensembl) and cloned into the pNL1.2[NlucP] vector (Promega). pNL1.2[NlucP]_
Hs_U3 was transfected into non-OA HACs or SW1353 cells (seeded at 15,000 cells/cm2) with Fugene6 and re-
seeded 2 h after transfection. U3 snoRNA promoter-reporter cells were exposed to OA synovial fluid (OA-SF; 
20% (v/v), pool of six donors), corresponding control (20% (v/v) of 0.9% NaCl), BMP7 (R&D Systems, Min-
neapolis, Minnesota, USA), IL1β (Life Technologies, Waltham, Massachusetts, USA) or TNFα (Sigma-Aldrich, 
Dorset, UK). For bioluminescence analysis cells were lysed with lysis buffer (Promega) and promoter-activity 
was measured with the Nano-Glo Luciferase Assay System (Promega) on a Tristar LB 942 (Berthold, Bad Wild-
bad, Germany). DNA-content was measured using a SYBR-GREEN (Invitrogen) assay. Relative differences were 
determined as compared to control conditions following correction for background and normalization by DNA 
content.
Gene expression. Cells were rinsed with 0.9% NaCl and cell lysis, RNA isolation and subsequent cDNA 
synthesis were performed using the Cells-to-Ct kit (ThermoFisher Scientific, Waltham, Massachusetts, USA). 
Alternatively, cells were disrupted with TRIzol reagent (Life Technologies), followed by RNA isolation and quan-
tification and cDNA synthesis as described  previously20. The real-time quantitative polymerase chain reaction 
was performed as described  previously5 and using validated primer sequences described in Supplementary 
Table 3. Ct-values were analyzed with the standard curve method and RNA (including non-coding- and messen-
ger-RNA) expression was normalized to cyclophilin expression or the relative DNA-content between treatments. 
DNA-content for normalization was measured in parallel wells receiving the identical treatment. DNA-content 
was measured using a DAPI and HOECHST staining further explained in “SUNsET-assay”. Differential gene 
expression was determined as a fold change compared to control conditions.
In-solution tryptic digestion and mass spectrometry proteomics. Cell lysates following U3 
snoRNA knockdown (or control) in SW1353 cells were  used21. Cells were harvested from triplicate wells of a 
six well plate with parallel wells used for confirmation of U3 snoRNA knockdown. In-solution tryptic digestion 
on 10 μg protein was undertaken as previously  described22. For the secretomes in-solution tryptic digestion was 
carried out on 10 µl of StrataClean resins (Agilent Genomics, 400,714) on 100 µg of protein for each sample 
as described  previously23. Liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis was per-
formed on trypsin digests using an Ultimate 3,000 Nanosystem (Dionex, ThermoFisher Scientific) online to a 
Q-Exactive Quadrupole-Orbitrap instrument (Thermo Scientific)24. Proteins were identified using an in‐house 
Mascot server (Matrix Science, London, UK). Search parameters used were as follows: enzyme; trypsin, peptide 
mass tolerances 10 ppm, fragment mass tolerance of 0.01 Da, 1+, 2+, and 3+ ions, with carbamidomethyl cysteine 
as a fixed modification and methionine oxidation as a variable modification, searching against the UniHuman 
Reviewed database, with a false discovery rate (FDR) of 1%, a minimum of two unique peptides per protein.
Label-free quantification of mass spectrometry proteomics data. Progenesis QI software (ver-
sion 4, Waters, Manchester, UK) was used to identify fold changes in protein abundance between U3 snoRNA 
knockdown and scrambled ASO control  condition25. Only unique peptides were used for quantification, and 
with p-values < 0.05, were considered to be differentially expressed (DE). Proteomic data has been deposited in 
the PRIDE ProteomeXchange and can be accessed using the identifier  PXD01725326.
Ingenuity pathway analysis. Functional analysis of differentially expressed proteins following U3 knock-
down in SW1353 cells was undertaken to evaluate the differences in protein abundance. Ingenuity pathway 
analysis has been performed as previously  described27.
Protein translation capacity. For a puromycilation  assay28,29, cultures were incubated for 15 min with 
5.4 µM puromycin (Sigma-Aldrich, Dorset, UK), immediately followed by washing steps with PBS and fixa-
tion for 20 min with 10% formalin (VWR). Wells were washed with PBS-T and treated for 10 min with 0.1% 
Triton X-100. Wells were blocked for 1.5 h with 1% (m/v) skimmed milk powder (ELK, Campina, Zaltbommel, 
the Netherlands) in PBS-T, followed by overnight incubation at 4 °C with the anti-puromycin antibody 12D10 
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(Sigma-Aldrich, Dorset, UK). After washing with PBS-T, wells were incubated for 1 h at room temperature with 
goat anti-mouse Alexa488 (ThermoFisher Scientific). Following a final wash step, the fluorescence signal inten-
sity was determined using a Tristar LB942 (Berthold, Bad Wildbad, Germany) equipped with excitation filter 
F485 and emission filter F353. Fluorescence data were normalized to DNA-content30. For that, the same wells 
were subsequently washed with HEPES-Buffered Saline (HBS), followed by 1 h incubation with 5 µg/mL DAPI 
(Invitrogen) plus 5 µg/mL HOECHST 33342 (Invitrogen) in HBS. After washing steps with HBS, fluorescence 
signal intensity was determined using a Tristar LB942 (Berthold), using the excitation filter F355 and emission 
filter F460.
RNA electrophoresis and northern blotting. Two micrograms total RNA was separated on a 6% PAA-
gel (6% PAA (Acrylamide/Bis-acrylamide 30:1); 1 × TBE (Tris–borate-EDTA; Merck, Darmstadt, Germany); 
8 M urea), electro-transferred to a Hybond-N membrane (GE Healthcare; Chicago, Illinois, USA) and immo-
bilized by UV-crosslinking (CL-1000, UVP). Membrane was pre-hybridized for 1 h at 62 °C under agitation in 
hybridization buffer (2 × SSC, 5 × Denhardts solution, 200 μg/ml fish sperm DNA, 0.1% SDS). Membrane was 
subsequently hybridized overnight with the U3 snoRNA probe (5 nM; Supplementary Table 4) at 62 °C under 
agitation. Non-hybridized probe was rinsed from the membrane using a series of SSC-SDS wash buffers. Mem-
brane was then incubated in blocking buffer [1 × PBS, 0.5% SDS, 0.1% I-Block (ThermoFisher Scientific)] for 
30 min, followed by 30 min incubation in blocking buffer containing 0.2 μg/ml Streptavidin-AP (Life Technolo-
gies). After washing with PBS the membrane was equilibrated with detection buffer (100 mM Tris–HCl pH 9.5; 
100 mM NaCl; 1 mM  MgCl2) and detection was carried out using CDP-Star (Sigma-Aldrich, Dorset, UK) and 
visualized/quantified using a Bio-Rad Chemidoc MP imaging system. U6 snRNA was detected as a reference 
RNA on the same membrane by reprobing and repeating the procedure in-full while using the U6 snRNA probe. 
Full length images of northern blots are shown in Supplementary Fig. 4. The U3 snoRNA signal was normalized 
by the signal for U6 snRNA and relative differences between conditions were calculated.
Statistical analyses. Statistical significance has been calculated using GraphPad Prism software version 
5.0 (La Jolla, California, USA) using paired or unpaired (depending on experiment) Student’s t-test . Depending 
on the experiment this was done 1-tailed or 2-tailed. Details per experiment are indicated in the corresponding 
figure legends. Conditions were compared to control and statistical significance was set at P < 0.05. To test for 
normal distribution of the input data, D’Agostino-Pearson omnibus normality tests were performed. All quan-
titative data sets presented here passed the normality tests. Bars in graphs represent mean ± standard deviation 
(SD).
Results
U3 snoRNA expression is decreased in cartilage and chondrocytes as function of OA. In order 
to find clues whether ribosome biogenesis is disturbed in osteoarthritic cartilage at the snoRNA level, a previ-
ously performed miRNA microarray experiment on young non-OA cartilage and old OA  cartilage19, on which 
probe sets for snoRNAs were also present, was reanalyzed (Supplementary Fig. 1). A number of snoRNAs was 
found to be differentially expressed between non-OA and OA cartilage and amongst these U3 snoRNA expres-
sion was significantly lower in OA cartilage (Fig. 1A). Since U3 is one of the most abundant snoRNAs play-
ing a key role in ribosome biogenesis, we investigated its involvement in chondrocyte homeostasis in more 
detail. To verify whether isolated OA chondrocytes have decreased U3 snoRNA levels, we measured U3 snoRNA 
expression in chondrocytes isolated from young non-OA and from old OA cartilage. Expression of U3 snoRNA 
in chondrocytes from OA cartilage was reduced (Fig.  1B) compared to non-OA chondrocytes. Reduced U3 
snoRNA expression in OA chondrocytes was accompanied with a distinctive cellular phenotype associated 
with (pre-)hypertrophic OA  chondrocytes5,31, with significantly reduced mRNA expression of chondrogenic 
genes COL2A1; ACAN; SOX9 and NKX3-2 and increased expression of chondrocyte hypertrophy-associated 
genes COL10A1; RUNX2; ALPL; MMP13; ADAMTS5; COX2 and IL6. Since there was an age difference between 
the non-OA cartilage/chondrocytes and the OA cartilage/chondrocytes used to determine differences in U3 
snoRNA expression (Fig. 1A/B), we next measured OA-dependent alterations in chondrocyte U3 snoRNA levels 
in an experimental mouse model for traumatic OA (destabilization of medial meniscus;  DMM32). Eight weeks 
post-DMM surgery knees were processed for U3 snoRNA in situ hybridization (ISH). A general reduction of 
U3 snoRNA ISH signal was observed in articular chondrocytes within the weight-bearing area of the joint in 
DMM-operated compared to sham-operated knees (Fig. 1C; red arrows). This was also observed in the menisci 
(Fig. 1C; blue arrowheads). U3 snoRNA levels were unaltered in chondrocytes in non-weight-bearing areas of 
the knee joints in sham-operated versus DMM-operated-mice (Fig. 1C; black arrows). Next, we asked whether 
OA-like conditions are capable of reducing U3 snoRNA expression levels in chondrocytes. To this end, non-OA 
human articular chondrocytes (HACs) from different donors were exposed to 20% (v/v) OA synovial fluid. U3 
snoRNA expression was significantly diminished in HACs exposed to OA synovial fluid (Fig. 1D). Exposing 
non-OA HACs to non-OA synovial fluid caused a significant increase in the expression of U3 snoRNA (Fig. 1E). 
A U3 snoRNA gene promoter-reporter assay in SW1353 cells (Fig. 1F) or in HACs (Fig. 1G) revealed that OA 
synovial fluid reduced U3 snoRNA promoter transcriptional activity in SW1353 cells and two out of three HAC 
donors. In addition we observed that U3 snoRNA promotor transcriptional activity is reduced in HACs by 
exposure to the two katabolic cytokines IL1β (Fig. 1H) or TNFα (Fig. 1I). Collectively, these data suggest that 
OA conditions are able to impact U3 snoRNA levels in chondrocytes.
U3 snoRNA levels influence the articular chondrocyte’s transcriptomic phenotype. It is 
unknown whether the level of U3 snoRNA expression influences the chondrocyte phenotype on the tran-
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scriptomic level. Therefore we altered U3 snoRNA expression levels in non-OA primary chondrocytes using 
a U3 snoRNA-specific antisense oligonucleotide (ASO). Following ASO transfections in five individual non-
OA chondrocyte cultures, reduced U3 snoRNA expression was confirmed (Fig. 2A). As a result, expression of 
COL2A1, SOX9, NKX3-2, RUNX2, MMP13 and IL6 was significantly reduced in all five chondrocyte isolates 
(Fig. 2B–G), but with variable levels of change. Reciprocally, we ectopically increased expression of U3 snoRNA 
moderately by transfecting primary chondrocytes with a U3 mini-gene (Fig. 3). The activity of the U3 mini-gene 
was confirmed by northern blot (Fig. 3A) and significantly elevated U3 snoRNA expression was confirmed in 
primary chondrocytes (Fig. 3B). The elevated U3 snoRNA expression levels resulted in upregulated levels of 
mRNAs coding for COL2A1 and NKX3-2 (Fig. 3C/E), while expression of SOX9 and IL6 transcripts was reduced 
(Fig. 3D/H). Expression of RUNX2 and MMP13 was also altered following ectopic expression of U3 snoRNA, 
albeit with strong inter-donor variability (Fig. 3F/G). Taken together, we demonstrated that ectopically-induced 
alterations in the expression levels of U3 snoRNA in articular chondrocytes change the chondrocyte’s transcrip-
tomic phenotype.
Chondrocyte rRNA levels are reduced in OA conditions and are regulated by U3 snoRNA. U3 
snoRNA is rate-limiting in the generation of mature  rRNAs12,33 and 18S rRNA in particular. To determine 
whether rRNA levels are altered in primary chondrocytes in OA conditions, we measured 18S, 5.8S and 28S 
rRNA expression. In concert with reduced U3 snoRNA levels in old OA chondrocytes (Fig. 1A/B), we observed 
reduced expression levels of 18S and 5.8S rRNAs in old OA chondrocytes, while 28S rRNA levels remained 
unaltered (Fig. 4A). Following the exposure of HACs to OA synovial fluid we observed a reduction of 18S and 
5.8S transcript levels (Fig. 4B), while 28S rRNA expression was not significantly altered. OA synovial fluid also 
reduced expression of 18S and 5.8S rRNAs in HACs (Fig. 4B), while an opposite response of 18S and 5.8S rRNA 
levels was detected when HACs were exposed to non-OA synovial fluid (Fig. 4B). In both conditions 28S rRNA 
expression was not significantly changed. Alteration of U3 snoRNA expression in primary chondrocytes (Figs. 2 
and 3) led to changes in chondrocyte rRNA levels. Reduction of U3 led to reduced 18S and 28S rRNA levels, with 
a sharp decrease of 5.8S rRNA levels in four out of five chondrocyte donors (Fig. 4C). Ectopic U3 expression led 
to increased 18S and 28S rRNA levels (Fig. 4D), while not changing 5.8S rRNA levels in three out of four chon-
drocyte donors. Overall, data demonstrate that 18S and 5.8S rRNA levels in chondrocytes are susceptible to OA 
conditions and rRNA transcript levels respond to U3 snoRNA expression.
U3 snoRNA levels influence the activity of the chondrocyte protein translation appara-
tus. Our data demonstrate alterations in chondrocyte rRNA levels in OA conditions and following knock-
down or ectopic expression of U3 snoRNA. Since rRNAs are the catalytically active subunits of the translating 
ribosome, we next investigated the consequences for overall protein translational capacity. Protein translational 
capacity was determined in chondrocytes from young non-OA and old OA cartilage and a significantly reduced 
translational capacity was observed in osteoarthritic chondrocytes (Fig. 5A). Translational capacity of chondro-
cyte cultures with diminished U3 snoRNA expression was significantly reduced (Fig. 5B), while ectopic induc-
tion of U3 snoRNA expression resulted in a mild, but significantly increased translational capacity (Fig. 5C). 
These data show that U3 snoRNA is able to change the chondrocyte’s translational capacity. To determine the 
full impact of U3 snoRNA knockdown and the concomitant reduction in rRNA levels on the chondrocyte trans-
lational apparatus, we subsequently conducted whole proteome analysis on SW1353 cells in which U3 snoRNA 
expression was reduced. A reduction of U3 snoRNA and concomitant reduction in 18S and 5.8S rRNA levels 
Figure 1.  Impaired expression of U3 snoRNA in osteoarthritic cartilage and chondrocytes. (A) Total RNA from 
non-OA or OA cartilage (n = 6 donors per group) was extracted and hybridized onto Affymetrix miRNA 4.0 
arrays. Using a probe set for Homo sapiens, differential expression of ncRNAs was determined (Supplementary 
Fig. 1). Expression of U3 snoRNA in microarray data is depicted as Log10 fold-change. (B) Expression levels of 
U3 snoRNA; mRNA expression of chondrogenic genes (COL2A1; ACAN; SOX9; NKX3-2), hypertrophic genes 
(RUNX2; COL10A1, ALPL), matrix-degrading enzyme genes (MMP13, ADAMTS5) and inflammatory mediator 
genes (COX2; IL6) were determined in chondrocytes derived from OA donors relative to non-OA controls 
(n = 4 donors per group) using RT-qPCR analysis. Data were normalized to cyclophilin expression. (C) DMM 
(n = 3) or sham surgery (n = 3) was performed in C57BL6/J male mice. Eight weeks post-surgery mice were 
sacrificed and knees prepared for U3 snoRNA ISH (representative images are depicted). Bottom images show 
the field-of-view in the boxes from the upper images at higher magnification. Red arrow heads: load-bearing 
articular cartilage surfaces; black arrow heads: non-load-bearing articular cartilage surfaces; blue arrow heads: 
meniscus. (D) Non-OA chondrocytes (n = 4 donors) were cultured for 24 h in the presence or absence of OA 
synovial fluid (OA SF) (20% (v/v); pool of 6 donors)). Expression of U3 snoRNA was determined relative to 
non-treated controls by RT-qPCR analysis. Results were normalized to total DNA content in parallel wells. (E) 
Non-OA chondrocytes (n = 4 donors) were cultured for 24 h in the presence or absence of synovial fluid from 
non-OA (non-OA SF) or OA (OA SF) donors [20% (v/v); pool of ten donors)]. Expression of U3 snoRNA was 
determined relative to control condition by RT-qPCR analysis. Data were normalized to cyclophilin expression. 
(F–I) SW1353 cells or non-OA HACs (n = 3 donors) were transfected with a pNL1.2[NlucP]_Hs_U3_promoter 
plasmid. Subsequently, cells were exposed to OA synovial fluid (20% (v/v), a pool of six donors), IL1β (10 ng/
ml) or TNFα (20 ng/ml) for 20 h and Nanoluc luciferase levels were measured. Data were calculated relative 
to control conditions (RLU). Statistical significance was determined using Student’s t-tests; (A/B/E–I) 2-tailed 
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Figure 2.  U3 snoRNA knock-down impacts the articular chondrocyte’s phenotype. Non-OA chondrocytes 
(n = 5 donors) were transfected with a U3 snoRNA ASO (U3 ASO) or scrambled (SCR) ASO and cultured for 
24 h. (A) Expression of U3 snoRNA; (B) COL2A1; (C) SOX9; (D) NKX3-2; (E) RUNX2; (F) MMP13 and (G) 
IL6 mRNA levels were determined by RT-qPCR analysis. Data from U3 ASO samples were calculated relative 
to controls transfected with the SCR ASO. Results were normalized to relative total DNA content in parallel 
wells. Statistical significance was determined using 2-tailed paired Student’s t-tests. Bars show the mean (± SD). 
*P < 0.05, **P < 0.01, ***P < 0.001 versus control conditions.
were confirmed (Supplementary Fig. 2). Ingenuity Pathway Analysis (IPA) analysis of the differential proteomes 
revealed that IPA networks “synthesis of protein”, “translation of protein”, “metabolism of protein” and “initiation 
of translation of mRNA” were top deregulated networks (Fig. 5D) and confirm a global impact of the reduc-
tion of U3 snoRNA expression on protein translational processes. Also networks involving transcription and 
expression of RNA were prominently represented in the IPA analysis. The differential proteome that is observed 
following U3 snoRNA reduction concerns a particular global upregulation of differentially expressed proteins 
(Supplementary Fig. 3), rather than a downregulation and contains a great number of protein species involved 
in the process of protein translation and ribosomal stress responses. An additional proteomic analysis of the 
secretome of these U3 snoRNA knockdown cells was conducted. Relevant to inflammatory responses in OA 
cartilage, we could demonstrate that secreted proteins involved in antagonizing inflammatory processes were 
present in the secretomes of U3 knockdown cells in lower abundance (Fig. 5E). Together these data show altera-
tions in chondrocyte protein translational activity following alterations in U3 snoRNA expression levels, with U3 
snoRNA impacting protein translation molecular routes.
U3 snoRNA expression is increased by BMP7. We previously demonstrated that bone morphogenetic 
protein 7 (BMP7) is capable of ameliorating the OA chondrocyte  phenotype5. Considering this anabolic action 
of BMP7 we evaluated whether U3 snoRNA and its subsequent rRNA targets can be induced in chondrocytes 
by BMP7. A U3 snoRNA promoter-reporter experiment in SW1353 cells or in non-OA HACs demonstrated 
that U3 snoRNA promoter transcriptional activity was induced following stimulation with BMP7 (Fig. 6A/B). 
In both chondrocyte cell models BMP7 induced U3 gene expression and increased expression of 18S and 5.8S 
rRNAs (Fig. 6C/D). The expression of 28S rRNA was not significantly altered. SW1353 cells stimulated with 
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BMP7 had an increased translational capacity (Fig. 6E), supporting the notion that the BMP7-mediated induc-
tion of U3 snoRNA and rRNA expression increases the chondrocyte’s translational capacity.
Discussion
U3 snoRNA is an abundant snoRNA with a pivotal function in the generation of mature 18S rRNA in 
 eukaryotes14. It’s snoRNP  biochemistry34 and mechanism-of-action35 have been extensively studied in the past 
decades. However, it was only recently described to be univocal involved in 18S rRNA generation in human 
 cells12. In contrast with its decade-long thorough molecular characterization, insight into its involvement in 
human disease is limited to a role in cell proliferation and  tumorigenesis12,36, while it remained unknown whether 
U3 snoRNA levels can be regulated via extracellular cues.
We demonstrate that in different osteoarthritic conditions the expression level of U3 snoRNA in articular 
chondrocytes is diminished. Reduced expression of U3 snoRNA was previously reported in serum of ageing 
 mice37, and as a result of nucleus pulposus ageing in  mice38. As a general study limitation in this field, we could 
not investigate the potential influence of age difference on U3 snoRNA expression between non-OA and OA 
cartilage/chondrocytes. To circumvent potential U3 expression interpretation issues, we reinforced our analyses 
by performing additional U3 snoRNA expression analyses in a murine model for OA and used synovial fluid 
from OA and non-OA individuals (no statistically significant age difference) on chondrocytes. Both as models 
in which age was not a potential confounder. Data from these models confirmed the OA-dependent reduction 
of chondrocyte U3 snoRNA expression. We could also conclude that reduced OA chondrocyte U3 snoRNA 
expression is, at least in part, mediated via diminished U3 gene transcription activity. This is the first data dem-
onstrating that the extracellular environment is capable of controlling cellular U3 snoRNA levels, thereby tuning 
the cell’s capacity to generate mature rRNA species. U3 snoRNA is transcribed from a dedicated transcriptional 
unit under the control of an RNA polymerase II-driven (RNAPII) promoter. Little is known about the control 
Figure 3.  Ectopic expression of U3 snoRNA impacts the chondrocyte’s phenotype. (A) Activity of the U3 mini-
gene in primary chondrocytes was confirmed by northern blot (n = 1) left panel. U3 snoRNA expression levels 
were calculated relative to control and normalized for U6 snRNA, right panel. Non-OA chondrocytes (n = 4 
donors) were transfected with the U3 mini-gene (10 ng plasmid/cm2) and cultured for 24 h. (B) Expression 
levels of U3 snoRNA; (C) COL2A; (D) SOX9; (E) NKX3-2; (F) RUNX2; (G) MMP13 and (H) IL6 gene 
expression levels were determined relative to control. Results were normalized to total DNA content in parallel 
wells. Statistical significance was determined using Student’s t-tests; (B) 1-tailed paired, (C–H) 2-tailed paired. 
Bars show the mean (± SD). *P < 0.05, **P < 0.01, ***P < 0.001 versus control conditions.
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of snoRNA transcription from dedicated transcriptional units, but our group previously reported that tran-
scriptional activity of another dedicated snoRNA gene (RMRP) can also be influenced via major chondrocyte 
signaling pathways during  chondrogenesis39. OA synovial fluid is a complex body fluid containing a plethora of 
catabolic morphogens and cytokines/chemokines40,41. Therefore we expect that the signaling molecule composi-
tion of OA synovial fluid acts on major chondrocyte signaling pathways, leading to the observed decreased U3 
snoRNA expression. Indeed our data demonstrated that the katabolic cytokines IL1β and TNFα attenuated U3 
promoter activity. Reciprocally, we demonstrate that non-OA synovial fluid and BMP7 are capable of inducing 
U3 snoRNA transcription and subsequent U3 snoRNA levels in chondrocytes.
A network of snoRNAs is involved in key ribosome biogenesis  processes16, and U3 snoRNA is a factor in the 
generation of 18S  rRNA14. Indeed our data show that manipulation of chondrocyte U3 snoRNA levels impacts 
18S rRNA levels, but also alters 5.8S and 28S rRNA levels in many instances. Taking into consideration the 47S 
pre-rRNA multi-cistronic origin of 18S rRNA, we speculate that aberrations in 18S rRNA levels may impact 5.8S 
and 28S rRNA levels possibly due to a 40S over 60S ribosomal subunit  imbalance42. Also other snoRNAs involved 
in 47S pre-rRNA processing could be impacted by OA conditions. Our unpublished data suggest deregulated 
chondrocyte U13 and RMRP snoRNA levels in OA conditions. This may provide additional explanations for 
the observed abberations in the levels of other rRNAs. In contrast with our current findings, other recent work 
demonstrated increased protein translation activity in OA  cartilage43–45. The OA cartilage used in our study was 
derived from end-stage (K&L grade 3–4) knee OA patients, while the OA grade of the human OA-lesioned carti-
lage presented by  others45 appears moderate. Taking into account that the reported increased protein translation 
activity in a rat model for OA seems to fade with progression into late OA  development45, we speculate that the 
contradictory observations may be explained by OA severity of the analyzed cartilage. This is further supported 
by the idea that an inflammatory component is much more dominant in early OA than in end-stage  OA46, and it 
Figure 4.  Chondrocyte ribosomal RNA expression is impacted in OA conditions and following alteration of 
U3 snoRNA levels. (A) rRNA expression levels were determined in OA and non-OA primary chondrocytes 
(n = 4 donors per group). (B) Non-OA chondrocytes (n = 4 donors) were cultured for 24 h in the presence or 
absence of synovial fluid from non-OA or OA donors [20% (v/v); pool of ten donors)]. Expression of rRNAs was 
determined relative to control condition by RT-qPCR analysis. Data were normalized to cyclophilin expression. 
(C) Non-OA chondrocytes (n = 5 donors) were transfected with a U3 snoRNA ASO or SCR ASO and cultured 
for 24 h and rRNA levels were measured using RT-qPCR. (D) Non-OA chondrocytes (n = 4 donors) were 
transfected with a U3 mini-gene (10 ng plasmid/cm2) and cultured for 24 h and rRNA levels were determined 
by RT-qPCR. Data were normalized to cyclophilin (A/B) or to relative total DNA content in parallel wells 
(C/D). Statistical significance was determined using Student’s t-tests; (A/B) 2-tailed unpaired, (C/D) 2-tailed 
paired. Bars show the mean (± SD). *P < 0.05, **P < 0.01, ***P < 0.001 versus control conditions.
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Figure 5.  U3 snoRNA expression levels influence the chondrocyte protein translation capacity and its 
proteome. Protein translational capacity was determined using a puromycilation assay in a number of 
conditions: (A) OA or non-OA primary chondrocytes (n = 4 donors per group), (B) in U3 snoRNA knockdown 
conditions in non-OA HACs (n = 4 donors) transfected with a U3 snoRNA ASO or SCR ASO, (C) and 
in non-OA primary chondrocytes (n = 4 donors) transfected with a U3 mini-gene (10 ng plasmid/cm2). 
Puromycilation data (A–C) were calculated relative to corresponding controls and were normalized to DNA 
content. Statistical significance was determined using Student’s t-tests; (A) 2-tailed unpaired, (B/C) 2-tailed 
paired. Bars show the mean (± SD). *P < 0.05, **P < 0.01, ***P < 0.001 versus control conditions. (D) SW1353 
cells were transfected with a U3 ASO or SCR control and cultured for 24 h (knockdown was confirmed 
in Supplementary Fig. 2), after which LC–MS/MS and label-free quantification was conducted. Ingenuity 
pathway analysis was performed on the differentially expressed proteins between conditions. Green nodes; 
decreased expression following knockdown, red nodes; increased expression following knockdown. Intensity 
of colour is related to a higher fold-change. Key to the main features in the networks is shown. (E) Upstream 
analysis in Ingenuity Pathway Analysis on the differentially expressed secreted proteins between conditions 
[(D) U3 snoRNA knockdown in SW1353]. This analyses linkage to differentially expressed proteins through 
coordinated expression, identify potential upstream regulators that has been observed experimentally to affect 
gene expression. Green nodes; decreased expression following U3 snoRNA knockdown, red nodes; increased 
expression following knockdown. Intensity of colour is related to a higher fold-change. Key to the main features 
in the networks is shown.
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was shown that the increase in translation activity could be recapitulated by IL1β45. This suggests that an increase 
in chondrocyte translation activity in OA may be predominantly related to early OA, while impaired protein 
translation may be a hallmark of end-stage OA.
While increased chondrocyte protein synthesis capacity in early OA may be related to mTOR signaling and 
imbalanced  autophagy47, it is unknown what the specific consequence is of a diminished capacity of global pro-
tein synthesis in relation to development or progression of osteoarthritis. We propose that U3 snoRNA-related 
reduction of chondrocyte protein translation affects the chondrocyte’s ability to maintain the molecular build-up 
of the cartilage proteinaceous ECM. Alterations in protein translation capacity may render articular cartilage 
vulnerable to any biomechanical, catabolic, traumatic or age-related changes in the joint that are associated 
with OA development and  progression2. In addition, our gene expression data, which are a representation of the 
overall chondrocyte differentiation  status3,4, show that alterations in chondrocyte U3 snoRNA levels affects its 
differentiation status. Data from the secretome proteomics analysis further show U3-dependent alterations in the 
levels of secreted proteins involved in balancing inflammatory pathways (A2M; AFP; HGF; AHSG). Together this 
shows that besides an influence on protein translation, alterations in chondrocyte U3 snoRNA levels additionally 
impact the chondrocyte’s homeostatic integrity.
Our whole proteome analysis uncovered that reduction of U3 snoRNA levels induces ribosome stress, 
which is indicated by aberrations in molecular pathways controlling key aspects of rRNA and ribosomal pro-
tein gene transcription (PGAM1; EDF1; MAPK1; AHCY; CARM1; FLNA), rRNA processing (FSCN1; RPS8; 
RAN; RPS24), ribosomal subunit transport (RAN), translation initiation (PHGHD; AKT1S1; EIF4H; ARPC5; 
TIAL1; EIF2S3; PABPC1; HSPB1; TPT1; FN1), chain elongation (DARS; EPRS; DDX3X) and protein folding/
chaperoning (AHSA1; HSPA8; HSP90; HSPB1) (Supplementary Fig. 3). Ribosome stress following reduction 
of U3 snoRNA expression was previously reported and is accompanied by stabilization of  p5312. Indeed we also 
observed increased expression of p53 after U3 snoRNA knockdown in SW1353 cells (data not shown). It was 
previously reported that p53 expression is also increased in OA  chondrocytes48. Stabilisation of p53 feeds back 
to ribosome biogenesis and down regulates translational  activity49,50. Besides the U3 snoRNA-dependent avail-
ability of rRNAs for ribosome biogenesis, this may provide a link between our observed OA-related impairment 
of U3 snoRNA expression levels in chondrocytes and their translational activity. In addition, IPA analyses of the 
U3 knock-down cellular proteome demonstrated that a great number of the differentially expressed proteins are 
targets of Myc (data not shown). We therefore speculate that stabilization of p53 may impact chondrocyte gene 
Figure 6.  U3 snoRNA and rRNA expression levels are regulated by BMP7. (A) SW1353 cells or (B) non-OA 
primary chondrocytes (n = 3) were transfected with a pNL1.2[NlucP]_Hs_U3_promoter plasmid. Subsequently, 
SW1353 cells (A) were exposed to 10 or 30 nM BMP7 and HACs (B) to 10 nM BMP7 for 20 h and Nanoluc 
luciferase levels were measured. Data were normalized and calculated relative to control conditions (RLU). (C) 
SW1353 cells and (D) non-OA primary chondrocytes (n = 4), were exposed to 1 nM BMP7 for 24 h. Expression 
of U3 snoRNA; 18S, 5.8S and 28S rRNA was determined relative to control conditions by RT-qPCR analysis. 
Results were normalized to cyclophilin expression. (E) SW1353 cells were exposed to 1 nM BMP7 for 24 h. 
Protein translation capacity was determined using a puromycilation assay and data were normalized for DNA 
content. Statistical significance was determined using Student’s t-tests; (A/B) 1-tailed unpaired, (C/E) 2-tailed 
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transcription processes via Myc, providing a potential explanation for the impact and discrepancies found in 
chondrocyte gene expression following alteration of U3 levels (Figs. 2, 3).
To comprehend the implications of the larger snoRNA  network16 on the function of the articular chondrocyte, 
other members of the non-canonical and canonical classes of snoRNAs should also be investigated. However, 
our study for the first time demonstrates the involvement of a snoRNA in articular chondrocyte biology. The 
OA-related impaired expression of U3 snoRNA has detectable consequences for articular chondrocyte protein 
translation capacity, rendering U3 snoRNA expression a potential therapeutic target in OA treatment. Indeed 
our data show that U3 snoRNA expression can be induced by the growth factor BMP7, providing a potential 
manner to target U3 snoRNA in OA chondrocytes.
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